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Background:  Although patients (pts) experiencing a myocardial infarction (MI) are at risk for sudden cardiac arrest (SCA) in the first several 
months after the index MI, ICD therapy has not reduced the rates of SCA in this pt group. The wearable cardiac defibrillator (WCD) is purported to 
offer protection as a potential bridge until pts reach a level of clinical stability when a more definitive decision about ICD implantation can be made.
Methods:  To evaluate the role of the WCD in post MI pts a prospective registry (Wearable Defibrillator Use after Myocardial Infarction: WAMI) 
was established. No pt met criteria for an ICD implant at the time of enrollment. Data were collected on 90-day survival, compliance, frequency of 
appropriate treatment and effectiveness of the WCD in preventing SCA.
Results:  Forty-three pts were enrolled with a mean age of 61 years (range 37-83), a predominant male gender (72%) and 81% with a left 
ventricular ejection fraction (LVEF) ≤ 35% (mean 28.84%±10.4%). Twenty-two pts experienced a probable ischemic sustained or non-sustained 
ventricular arrhythmia in association with the MI. Post-discharge, one pt experienced a 43 second episode of sustained VT @ 220 BPM, successfully 
terminated by the WCD. A second pt experienced an inappropriate treatment due to oversensing of signal artifact. No deaths were observed. At 90 
days, 51% of pts had an EF > 35% and therefore no longer qualified for a primary prevention (PP) ICD implantation. Another 19% qualified for and 
underwent a PP ICD implantation. Thirteen pts (30%) were lost to follow-up. The average length of use was 58.3 days (range 3-146) with an average 
daily use of 19.8 hours (range 0.5-23.3). The length of use was highly correlated to average daily use (p < 0.001) and age (p < 0.005).
Conclusions: 1. A substantial percentage of pts will have significant improvement in left ventricular function within the first 90 days after a 
myocardial infarction, placing them at lower risk for SCA thereafter, and therefore obviating the need for prophylactic defibrillator implantation.
2. Use of the WCD can be protective against SCA during this vulnerable period.
3. Compliance with the use of this device is high.
